Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta‐analysis of eight cohort studies
- 27 September 2012
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 111 (3b), E71-E77
- https://doi.org/10.1111/j.1464-410x.2012.11527.x
Abstract
What's known on the subject? and What does the study add? Over the last few years, several observational studies examined the association of statin use with the risk of biochemical recurrence of prostate cancer after definitive local therapy. The objective of our present study was to summarise available evidence on this subject using the method of meta-analysis. Combined evidence from eight cohort studies did not definitively support the hypothesis that statins influence the risk of biochemical recurrence. However, there was considerable disagreement between individual studies in reported findings and conclusions. To perform a systematic review and meta-analysis of clinical studies with statin use as the exposure variable and biochemical recurrence after definitive local therapy for prostate cancer as the outcome. Relevant publications were identified through PubMed/Medline/Embase databases. Pooled estimates of the hazard ratios (HRs) were computed using the inverse-variance weighting approach. Heterogeneity was assessed using the Cochran's Q test. We identified a total of eight eligible studies, all based on the retrospective cohort design. Five of these were based on radical prostatectomy (RP) series and three on radiotherapy (RT) series. There was evidence of heterogeneity in the entire set of eight studies (P = 0.002) as well as in the RP series (P = 0.05) and in the RT series (P = 0.01), when these were considered separately. Based on the random effects inverse-variance weighting approach, pooled estimates of the HRs for the risk of biochemical recurrence in statin users v non-users were 0.91 (95% confidence interval [CI] 0.72-1.13) for the entire set of eight studies, 1.02 (95% CI 0.80-1.29) for the RP series and 0.71 (95% CI 0.44-1.16) for the RT series. The pooled estimates of the HRs were not significantly different from the null value in this meta-analysis; however, evidence of heterogeneity between the studies was present.Keywords
This publication has 36 references indexed in Scilit:
- Statin Use as a Moderator of Metformin Effect on Risk for Prostate Cancer Among Type 2 Diabetic PatientsDiabetes Care, 2012
- Statin Use and Risk of Prostate Cancer in a Population of Men Who Underwent BiopsyJournal of Urology, 2011
- Association of Statin Use With Pathological Tumor Characteristics and Prostate Cancer Recurrence After SurgeryJournal of Urology, 2011
- Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination SurveyJournal of Clinical Oncology, 2010
- The Association Between Statin Use and the Diagnosis of Prostate Cancer in a Population Based CohortJournal of Urology, 2010
- Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe SwedenJournal of Clinical Oncology, 2010
- Statin medication use and the risk of biochemical recurrence after radical prostatectomyCancer, 2010
- Statin and NSAID use and prostate cancer riskPharmacoepidemiology and Drug Safety, 2010
- Statin use and prostate cancer risk in a large population-based settingCancer Causes & Control, 2008
- Publication Bias: A Brief Review for CliniciansMayo Clinic Proceedings, 2000